In vitro antimicrobial activity of cefclidin and its therapeutic efficacy in respiratory infections

Akira Watanabe, Yoshihiro Honda, Yutaka Tokue, Naoto Kitamura, Satoru Shoji, Hiroaki Kikuchi, Masakichi Motomiya, Seiichi Aonuma, Kazuo Sato

    Research output: Contribution to journalArticlepeer-review


    The in vitro antimicrobial activity of cefclidin (CFCL), a new cephem antibiotic with a potent antipseudomonal activity for parenteral use, was measured and its therapeutic efficacy especially in respiratory infections was evaluated. The minimum inhibitory concentrations (MIC's) of CFCL, ceftazidime (CAZ), ceftizoxime (CZX) and latamoxef (LMOX= moxalactam) against 20 strains each of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa were determined by a micro-broth dilution method using the Dynatech MIC 2000 system. As shown by MIC's, CFCL was as active as other agents against S.aureus. On the other hand, CFCL was the most active against Enterobacteriaceae and P.aeruginosa of the four agents tested. A daily dose of 2 or 4 grams of CFCL was given intravenously for 6-16 days (mean 12.5 days) to 13 patients: 3 each had acute pneumonia and infected bronchiectasis, 2 with lung abscess and 1 each with chronic bronchitis, diffuse panbronchiolitis, infection super-vening on old pulmonary tuberculosis, secondary infection in association with lung cancer and chronic complicated urinary tract infection. The clinical effects of CFCL were excellent in one, good in 11 and fair in one. Two cases of lung cancer without clinical symptom and signs of infection were excluded from the clinical evaluation. Three strains of P.aeruginosa, two strains of S.marcescens and one strain of Haemophilus influenzae were identified as causative organisms and all of them were eradicated by an administration of CFCL. In 15 patients who received CFCL, drug exanthema was observed in two, and an elevation of serum transaminase and proteinuria were observed in one. These adverse reactions disappeared after completion of the therapy. From the above results, we conclude that CFCL is one of the most useful cephem antibiotics for parenteral use as a first choice in the treatment of respiratory infections.

    Original languageEnglish
    Pages (from-to)267-272
    Number of pages6
    Publication statusPublished - 1992 Sep


    • Cefclidin

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'In vitro antimicrobial activity of cefclidin and its therapeutic efficacy in respiratory infections'. Together they form a unique fingerprint.

    Cite this